Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
Researchers at La Jolla Institute for Immunology have found that T cells can recognize shared viral targets between multiple coronaviruses, including common cold coronaviruses and SARS-CoV-2. This cross-reactivity could be harnessed to develop vaccines that protect against multiple types of coronaviruses, including SARS-CoV-2.
Scientists at La Jolla Institute for Immunology found that MAIT cells can be tuned to fight different pathogens via their metabolism, with two distinct subtypes responding to sugar and fat. This discovery may inspire new vaccines and cell therapies to boost the immune response against specific pathogens.
Researchers discovered a 'cocktail' of human antibodies that show promise in fighting severe SARS-CoV-2 infections, including Omicron variants. The study revealed how the original Moderna vaccine could prompt the body to produce these broad-spectrum antibodies.
Researchers at La Jolla Institute for Immunology have developed a high-resolution view of the LCMV glycoprotein, revealing its structure and potential vulnerabilities. The breakthrough enables the development of an engineered antibody that can prevent LCMV disease, offering a new route to treatment.
The new grant enables LJI to lead the Human Immunology Project Consortium Data Coordinating Center, providing access to human immunoprofiling data from over 11,000 participants. This will fuel scientific collaboration in understanding immune responses to viruses, autoimmune diseases, and more.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
Researchers at La Jolla Institute for Immunology have discovered that OGT regulates mTOR, a key protein for mitochondrial powerhouses, keeping cells healthy. The study may lead to important medical advances in understanding cancers, diabetes, and cardiovascular disease.
Researchers at La Jolla Institute for Immunology have confirmed that the smallpox vaccine MVA-BN (JYNNEOS) can teach T cells to recognize and fight the mpox virus. The study suggests that the JYNNEOS vaccine may provide protection against severe disease and could be effective in immunocompromised individuals.
Researchers at La Jolla Institute for Immunology have found that the inflammatory molecule LIGHT leads to airway remodeling and long-term breathing issues in severe asthma. Therapeutics targeting LIGHT could reverse airway and lung damage, offering a potential long-term treatment for asthma.
Researchers at La Jolla Institute for Immunology discovered a direct link between TET protein loss of function and missing genes in embryonic stem cells, which can lead to cancer growth. The study found that TET proteins are crucial for maintaining genome stability, and their loss results in aneuploidies, a common feature of cancer cells.
Researchers at La Jolla Institute for Immunology have developed a new therapy for Lassa fever using a trio of rare human antibodies that can block viral infection. The therapy, called Arevirumab-3, was tested in non-human primates and proved 100% effective in treating the disease.
Researchers will investigate immune system differences between men and women to better understand neurodegenerative diseases. The study aims to identify why certain neurological diseases primarily affect males or females, and how this difference impacts disease progression.
Researchers at La Jolla Institute for Immunology have discovered a rare T cell defect tied to the risk of developing MAC disease. People with this defect have fewer specialized Th1* cells, which robs them of an effective immune response to MAC bacteria.
Researchers found that a 'slow delivery, escalating dose' vaccination strategy can prompt B cells to spend months mutating and evolving their antibodies, leading to more effective long-lasting vaccines. This breakthrough has implications for vaccines against pathogens like influenza, malaria, and SARS-CoV-2.
Researchers at La Jolla Institute for Immunology discovered how Zika virus forces dendritic cells to churn out lipid molecules, allowing the virus to build copies of itself. This study provides a major step forward in developing antiviral therapies against multiple flavivirus infections.
Scientists at La Jolla Institute for Immunology discover how gut barrier cells send secret messages to patrolling T cells, keeping them alive and active. The study sheds light on conditions like inflammatory bowel disease and highlights the importance of HVEM protein in maintaining a healthy gut microbiome.
A new study found that adults have stable immune memory to common cold coronaviruses, which could lead to similar protection against SARS-CoV-2. The findings suggest that COVID-19 booster shots may be critical for long-term immunity.
Researchers have published the first-ever look at a key stage in the life cycles of measles and Nipah viruses, revealing how future therapies might stop these viruses. The study identifies how paramyxoviruses utilize a host cell lipid for viral spread, providing a new target for developing inhibitors of the assembly process.
Researchers at La Jolla Institute for Immunology have identified a critical protein, GSPT1, that facilitates Lassa virus infection. Targeting this protein with an existing drug candidate, CC-90009, shows promise in reducing Lassa virus growth without cell toxicity.
Scientists have discovered a new, high-resolution view of the rabies virus glycoprotein, which could lead to more effective vaccines. The study's findings suggest that a better-shaped vaccine could provide lifelong protection against the deadly disease.
A new study published in Cell compares the four types of COVID-19 vaccines and reveals that most people retain some immune response to SARS-CoV-2. The researchers found that immune memory may not prevent infection but helps fight severe disease.
A study published in Nature Cardiovascular Research reveals that rare T cells targeting apolipoprotein B can contribute to inflammation and atherosclerosis progression. Researchers discovered these cells resemble regulatory T cells but develop a new identity as heart disease develops.
Researchers found that hypoxia can activate immune cells called ILC2s, which respond to harmless environmental allergens and drive mucus production and inflammation in the lungs. The study identifies adrenomedullin as a new target for treating inflammatory and allergic lung diseases.
Scientists discovered that intermittent dosing of PI3Kδ inhibitors can reduce toxicity while maintaining anti-tumor immunity in patients with head and neck cancers. This finding holds promise for improving treatment outcomes and saving lives.
Researchers at La Jolla Institute for Immunology discovered a Zika virus mutation that boosts its ability to replicate and infect humans. This mutation allows the virus to evade protective immunity from previous dengue exposure, increasing its transmission potential.
Scientists have discovered a promising strategy to treat Ebola virus infections by targeting cellular protein GSPT1, which the virus hijacks for polymerase function. An experimental drug CC-90009 degrades GSPT1, halting viral multiplication.
Scientists have identified a clear genetic signature of Parkinson's disease in people's memory T cells, which could lead to new therapies and diagnostics. The study found that targeting these genes may help stop T cells from attacking brain cells in Parkinson's.
Researchers at La Jolla Institute for Immunology have developed two human antibodies that target Ebola virus and Sudan virus, showing promise for a powerful antiviral therapy. The antibodies, 1C3 and 1C11, can block three glycoprotein sites on the virus at once and target the fusion machinery used by the viruses to infect host cells.
A recent study by La Jolla Institute for Immunology researchers has identified new subsets of CD4+ 'helper' T cells that are linked to autoimmune disease risk. The team used single-cell RNA sequencing to compare gene expression in over 1 million CD4+ T cells from 89 healthy donors, revealing sex-based differences in immune cell functio...
A new study from the La Jolla Institute for Immunology reveals that two groups of regulatory CD4+ T cells develop at different times to combat acute inflammation. The early Tregs reduce autoimmune damage, while the second wave shuts down the entire immune response to signal infection clearance.
Four COVID-19 vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize variants of concern, including Delta and Omicron. Fully vaccinated people have fewer memory B cells and neutralizing antibodies against the Omicron variant.
Researchers at La Jolla Institute for Immunology found that macrophages in artery walls can sense octanal, leading to inflammation and atherosclerosis. By blocking this detection, they reversed disease progression. Further research is needed to explore the role of olfactory receptors in cardiovascular diseases.
Scientists at La Jolla Institute for Immunology have discovered a link between TET enzyme deficiency and the formation of unusual DNA structures, such as G-quadruplexes and R-loops, which contribute to genomic instability. The study suggests that regulating these structures may be key to controlling cancer development.
Researchers at La Jolla Institute for Immunology identified Th1* cells as a key marker in the body's immune signature following BCG vaccination. The study found that these cells respond well to the vaccine and can help fight the Mycobacterium tuberculosis bacterium that causes TB.
A new particulate saponin/TLR agonist vaccine adjuvant has been shown to alter lymph flow and modulate adaptive immunity. This study demonstrates the potential of this ingredient as a more effective vaccine booster.
Scientists at La Jolla Institute for Immunology and MIT have discovered a new adjuvant called SMNP, which combines saponin and TLR agonist to boost the protective power of vaccines. The study found that SMNP triggers a strong immune response in mice, promoting lymphatic drainage and activating multiple parts of the immune system.
New research reveals how genetic variations impact COVID-19 case severity, focusing on non-classical monocytes and their role in the immune response. The study identifies potential targets for therapies to boost immune cell function and improve disease outcomes.
A recent study by La Jolla Institute for Immunology has identified a trio of proteins - TWEAK, TNF, and IL-17 - that control inflammation in psoriasis patients. Targeting this protein complex may lead to more effective treatments for the disease.
Erica Ollmann Saphire and her team at the La Jolla Institute for Immunology have received a $2.6 million grant to develop a pan-coronavirus vaccine. The team aims to create a single vaccine that can protect against future outbreaks of any coronavirus, including SARS-CoV-2 variants.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
A new study from La Jolla Institute for Immunology shows that the Moderna COVID-19 vaccine generates durable T cell memory and antibodies, even in people over 70. The researchers found strong CD4+ and CD8+ T cell responses to the vaccine, comparable to those seen in recovered COVID-19 patients.
Scientists at the La Jolla Institute for Immunology have discovered that Vitamin C and TET proteins can work together to generate stable induced Tregs, which could potentially treat autoimmune diseases. The study reveals an intriguing connection between TET enzymatic activity, Vitamin C and IL-2/STAT5 signaling.
Researchers at La Jolla Institute for Immunology report that T cells can be engineered to clear tumors without succumbing to T cell exhaustion. Altering CAR T cells to overexpress BATF boosts the 'effector' program, making T cells better against solid tumors.
Researchers at La Jolla Institute for Immunology found that people who recovered from COVID-19 or received Moderna or Pfizer-BioNTech vaccines have cross-reactive T cells that can target several SARS-CoV-2 variants. This reactivity is key to the body's immune response, allowing it to kill infected cells and stop severe infections.
Researchers at La Jolla Institute for Immunology found that TET enzymes play a crucial role in keeping immune cells on a healthy track, suggesting potential new avenues for controlling cardiovascular disease. The study also identified the minor but important role of TDG enzyme in immune cell demethylation.
New research suggests that treating cancer patients with anti-CTLA4 therapies before anti-PD1 treatment can improve overall survival. High numbers of T follicular regulatory (Tfr) cells in tumors may be to blame for the lack of response to anti-PD1 therapies.
The La Jolla Institute for Immunology has launched the Cancer Epitope Database and Analysis Resource (CEDAR), a new global cancer immunology resource, thanks to $4.2 million in National Cancer Institute funding. Researchers can now easily search and contribute data on potential immune system targets on various types of cancer cells.
The La Jolla Institute for Immunology has partnered with Synbal, Inc. to develop multi-gene, humanized mouse models for COVID-19 research. These new models are expected to provide a better understanding of SARS-CoV-2 infection and disease severity, enabling the development of more effective vaccines and therapies.